Based in Watchung, New Jersey, USA, GY Highland Biotech LLC is the sister company of Shaanxi Gaoyuan In Vitro Diagnostic Reagents Co., Ltd., an innovative solution researcher and manufacturer of in vitro diagnostics with a growing portfolio in cancer diagnostics. The company has developed its patented Folate Receptor-mediated Detection (FRD™) staining solution, designed to detect precancerous and cancerous lesions on the cervix in real-time, into a platform for cancer diagnosis with continuing R&D investments to expand its product portfolio into other clinical and research areas.
GY Highland Biotech LLC is responsible for the sales and marketing expansion for the global market. FRD™ has CE marking for use throughout Europe and CFDA approval for China. It is currently available in multiple regions and countries around the world.
GY Highland Biotech LLC hopes for inclusion in government funded cervical cancer screening programs, as well as non-government and corporate funded screening programs in developing countries where limited or no resources are available. In a parallel approach, efforts are aimed to pursue usage in the clinic setting by working closely with Key Opinion Leaders to obtain their endorsements for local and global marketing recognition.
We are engaged in the process of identifying suitable distributors to collaborate with us in the global market. This process has been initiated in Europe, Central and South America, Africa, Asia and the Middle East.
Shaanxi Gaoyuan In Vitro Diagnostic Reagent Co., Ltd.
Established on June 30 2010, in Xian, China, Gaoyuan has been constantly developing advance medical products and technology.
Management team : Yan Wenguang, a corporate legal representative, has been working with diagnostic reagents and medical equipment for over 20 years. Weiyuan Micro-Biomedical Research Institute, the subsidiary company of Shaanxi Gaoyuan In Vitro Diagnostic Reagents Co. Ltd., is a group of 25 researchers holding Master’s and Ph.D. degrees in biotechnology, pharmaceutical engineering, bioengineering, and medical testing. The company owns 11 patents with 12 more patents pending. Its FRD™ epithelial cell staining solution has participated in the “China Rural Women’s Cervical Cancer and Breast Cancer Screening Project” for six consecutive years, providing doctor education and training to provide free medical technology to poor families.